Related Experiment Videos
Urapidil therapy for acute hypertensive crises in infants and children
Insights
Urapidil effectively treats hypertensive crises in pediatric patients post-cardiovascular surgery. This medication rapidly lowers blood pressure with minimal serious side effects, making it a recommended option for children.
Area of Science:
- Pediatric Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Hypertension is a critical complication following cardiovascular operations in infants and children.
- Effective and safe management of hypertensive crises in pediatric patients is essential.
Purpose of the Study:
- To evaluate the efficacy and safety of urapidil infusion for treating acute and severe hypertension in pediatric patients after cardiovascular surgery.
Main Methods:
- Urapidil infusion was administered to 19 infants and children experiencing hypertensive crisis post-cardiovascular operation.
- Blood pressure, central venous pressure, heart rate, urine volume, and serum electrolytes were monitored.
Main Results:
- Urapidil effectively reduced blood pressure within 15 minutes in all patients.
- A decrease in central venous pressure was observed; heart rate and urine volume remained unchanged.
- Transient electrolyte shifts (decreased sodium, increased potassium) occurred; one case of hypotension required dose adjustment, with no serious adverse events reported.
Conclusions:
- Urapidil is a safe and effective treatment for hypertensive crises in pediatric patients following cardiovascular surgery.
- The drug demonstrates rapid efficacy and a favorable safety profile in this population.
Abstract:
In 19 infants and children with acute and severe hypertension following a cardiovascular operation urapidil infusion was started for treatment of the hypertensive crisis. In all patients blood pressure was effectively reduced within 15 min. The drop in systemic blood pressure was combined with a reduction of central venous pressure. Heart rate and urine volume remained unaltered. Serum electrolytes after 12-24 h therapy showed a slight but significant decrease in serum sodium and an increase in serum potassium concentration. In one case urapidil treatment had to be interrupted because of hypotension. In this case the urapidil therapy was tolerated later in lower doses. Serious side effects were not observed. In our experience urapidil can be recommended for the treatment of hypertensive crises in children.